Dr David Gilham | Vice President Of Research And Development

Dr David Gilham, Vice President Of Research And Development, Celyad

Dr. David Gilham is Vice-President R&D of Celyad. He heads the implementation of Research and Development strategy for the immune-oncology programs. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.


Conference Day 1 - Tuesday 31st March 2020 @ 14:20

Exploiting Natural Receptors to broaden the horizon of CAR-T

last published: 05/Dec/19 09:46 GMT

back to speakers